Stuttgart - Delayed Quote EUR

Zai Lab Ltd (1ZLB.SG)

Compare
2.3600 -0.0200 (-0.84%)
As of 8:10:43 AM GMT+1. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 1ZLB.SG

Recent News: 1ZLB.SG

View More
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
Business Wire 2 hours ago
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
Business Wire 2 hours ago
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
Business Wire 15 hours ago
Zai Lab (NASDAQ:ZLAB) shareholders have endured a 59% loss from investing in the stock three years ago

Zai Lab (NASDAQ:ZLAB) shareholders have endured a 59% loss from investing in the stock three years ago
Simply Wall St. 17 days ago
Zai Lab Announces Participation in Investor Conference in January 2025

Zai Lab Announces Participation in Investor Conference in January 2025
Business Wire 29 days ago
Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint

Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint
TipRanks last month
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
Business Wire last month
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List

Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
Business Wire last month
Exploring Three High Growth Tech Stocks in the United States

Exploring Three High Growth Tech Stocks in the United States
Simply Wall St. last month
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
Business Wire last month
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
Business Wire last month
View More

Related Tickers

WXXWY WuXi Biologics (Cayman) Inc.
4.3200
+3.10%
 
AVBP ArriVent BioPharma, Inc.
25.46
-5.23%
 
XNCR Xencor, Inc.
22.28
-4.91%
 
INAB IN8bio, Inc.
0.3199
+2.39%
 
CGON CG Oncology, Inc.
29.66
-2.63%
 
GUTS Fractyl Health, Inc.
1.8550
-2.37%
 
OCEA Ocean Biomedical, Inc.
0.6065
-9.22%
 
KYTX Kyverna Therapeutics, Inc.
3.5390
-6.87%
 
OMER Omeros Corporation
9.34
-5.56%
 
INBX Inhibrx Biosciences, Inc.
14.53
-3.00%